A study conducted by the department of Ophthalmology, New Zealand National Eye Centre, at The University of Auckland has demonstrated the potential for intense regulated pulsed light (IRPL) therapy to significantly decrease symptoms of dry eye disease reported in ocular surface disease index (OSDI), standard patient evaluation of eye dryness questionnaire (SPEED) and symptom assessment questionnaire in dry eye (SANDE) symptomology scores after four weeks of treatment.
In recent years, several meibomian gland dysfunction (MGD) treatment methodologies have been developed in response to increasing prevalence of dry eye symptoms. IRPL is one therapy that has demonstrated favourable clinical efficacy and tolerability to treat various dry eye conditions. As such, it has become the current standard treatment for clinical MGD management.
The controlled study, conducted in New Zealand, involved 87 symptomatic participants (58 female, mean ± SD age, 53 ± 16 years) with clinical signs of MGD. Participants were enrolled in a prospective, double-masked, parallel-group, randomised, placebo-controlled trial.
During the study, the patients received either four or five homogeneously sequenced light pulses or placebo treatment to both of their eyes (E-Eye IRPL E-Swin, France). Their visual acuity, dry eye symptomology, tear film parameters and ocular surface characteristics were examined immediately before treatment on days zero, 15, 45, 75, and four weeks after treatment on day 105. The study also examined inflammatory, expression of goblet cell, and eyelid swab microbiology cultures at days zero and 105.1
The study showed that IPL therapy provides significant improvements in dry eye symptomology, evidence of increase in the thickness of tear film lipid layer and meibomian gland capping. The results from the study also showed five-flash IPL treatment presented superior clinical efficacy to four flash. Finally, corynebacterium macginleyi growth appeared to be inhibited following both four and five-flash IPL treatment.1
- Jennifer P. Craig. 2020. “Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction” Elsevier.